Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control

AIDS

Volumn 25, Issue 18, 2011, Pages 2217-2226

  Van Manen, Daniëlle ^a   Gras, Luuk ^b   Boeser Nunnink, Brigitte D ^a   Van Sighem, Ard I ^b   Maurer, Irma ^a   Mangas Ruiz, Marga M ^a   Harskamp, Agnes M ^a   Steingrover, Radjin ^a   Prins, Jan M ^a   De Wolf, Frank ^b   Van 'T Wout, Angélique B ^a   Schuitemaker, Hanneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

Author keywords

CCR5; HCP5; HIV 1; HLA C; host genetics; viral load

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HLA C ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC REGULATION; GENOTYPE; HCP5 GENE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV SEROPOSITIVITY; HIV-1; HLA-C ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5; TIME FACTORS; VIRAL LOAD;

EID: 80855147480     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834bec9c     Document Type: Article

References (56)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
2. De Wolf F, Spijkerman I, Schellekens PThA, Langendam M, Kuiken CL, Bakker M, et al. AIDS prognosis based on HIV-1 RNA, CD4RT cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-1806. (Pubitemid 27500955)
3. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes in the course of HIV-1 infection. Nature Med 1996; 2:405-411. (Pubitemid 26193012)
4. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA BM5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-2714. (Pubitemid 30159236)
5. Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 2007; 179:3133-3143.
6. De Roda Husman AM, Koot M, Cornelissen M, Brouwer M, Broersen SM, Bakker M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-890. (Pubitemid 27490625)
7. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273:1856-1862. (Pubitemid 26322495)
8. Meyer L, Magierowska M, Hubert J-B, Rouzioux C, Deveau C, Sanson F, et al. Early protective effect of CCR5 D32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997; 11:F73-F78. (Pubitemid 27423287)
9. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
10. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, Van 't Wout AB, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23:19-28.
11. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419-426.
12. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 2008; 3:e3907.
13. Dorrucci M, Rezza G, Porter K, Phillips A. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-534. (Pubitemid 46214395)
14. Muller V, Maggiolo F, Suter F, Ladisa N, De LA, Antinori A, et al. Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog 2009; 5:e1000454.
15. Gras L, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, et al. Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One 2009; 4:e7365.
16. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82:7932-7941.
17. van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol 2010; 84:3576-3585.
18. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312. (Pubitemid 36378357)
19. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102:18514-18519. (Pubitemid 43011257)
20. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94:1890-1895. (Pubitemid 27113932)
21. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217. (Pubitemid 27064707)
22. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
23. Schuurman R, Nijhuis M, Van Leeuwen R, Schipper P, De Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type I RNA load and appearance of drug resistant virus populations in persons treated with Lamivudine (3TC). J Infect Dis 1995; 171:1411-1419.
24. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-645.
25. Schellens IM, Navis M, van Deutekom HW, Boeser-Nunnink B, Berkhout B, Kootstra NA, et al. Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic. AIDS 2011; 25:1691-1700.
26. De Wolf F, Lange JMA, Houweling JTM, Coutinho RA, Schellekens PThA, Van der Noordaa J, et al. Numbers of CD4R cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis 1988; 158:615-622.
27. Van Griensven GJ, de Vroome EM, Goudsmit J, Coutinho RA. Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ 1989; 298:218-221. (Pubitemid 19045133)
28. Steingrover R, Pogany K, Fernandez GE, Jurriaans S, Brinkman K, Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22:1583-1588.
29. van Manen D, Delaneau O, Kootstra NA, Boeser-Nunnink BD, Limou S, Bol SM, et al. Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. PLoS One 2011; 6:e22208.
30. Van 't Wout AB, Schuitemaker H, Kootstra NA. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat Protoc 2008; 3:363-370. (Pubitemid 351372226)
31. Faul F, Erdfelder E, Lang AG, Buchner A. GMPower 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39:175-191.
32. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
33. Herbeck JT, Gottlieb GS, Li X, Hu Z, Detels R, Phair J, et al. Lack of evidence for changing virulence of HIV-1 in North America. PLoS One 2008; 3:e1525.
34. Muller V, Ledergerber B, Perrin L, Klimkait T, Furrer H, Telenti A, et al. Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 2006; 20:889-894. (Pubitemid 43731571)
35. Troude P, Chaix ML, Tran L, Deveau C, Seng R, Delfraissy JF, et al. No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 2009; 23:1261-1267.
36. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73. (Pubitemid 29028340)
37. Notermans DW, de Wolf F, Oudshoorn P, Cuijpers HT, Pirillo M, Tiller FW, et al. Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses 2000; 16:1507-1517.
38. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-2591. (Pubitemid 38402336)
39. Yoon W, Ma BJ, Fellay J, Huang W, Xia SM, Zhang R, et al. A polymorphism in the HCP5 gene associated with HLABM5701 does not restrict HIV-1 in vitro. AIDS 2010; 24: 155-157.
40. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445-448. (Pubitemid 47057672)
41. Koning FA, Koevoets C, van der Vorst TJ, Schuitemaker H. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther 2005; 10:231-237. (Pubitemid 41151029)
42. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, et al. Sensitivity to inhibition by b-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996; 93:15382-15387. (Pubitemid 27009609)
43. Scarlatti G, Tresoldi E, Björndal A° , Fredriksson R, Colognesi C, Deng HK, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine mediated suppression. Nature Med 1997; 3:1259-1265. (Pubitemid 27508828)
44. Gali Y, Berkhout B, Vanham G, Bakker M, Back NK, Arien KK. Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology 2007; 364:140-146. (Pubitemid 46829281)
45. Schuitemaker H, Van't Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9 (Suppl 1):S5.
46. Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 2009; 25:795-802.
47. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, Souyris C, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24:2305-2312.
48. Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, et al. HLAC cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-1294.
49. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-289. (Pubitemid 38667619)
50. Navis M, Matas DE, Rachinger A, Koning FA, van Peter S, Kootstra NA, et al. Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS One 2008; 3:e2422.
51. Barouch DH, Letvin NL. HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Lancet 2004; 364:10-11. (Pubitemid 38968609)
52. Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM, et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med 2010; 16:995-997.
53. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
54. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci USA 2007; 104:17441-17446. (Pubitemid 350219857)
55. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
56. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDSfree HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.